Director & Scientific Advisory Board Chair Xiaodong Wang Files Form 144 to Sell $47.1M in BeOne Medicines

Executive Summary

On September 8, 2026, Xiaodong Wang, Director and Chair of the Scientific Advisory Board at BeOne Medicines Ltd., filed a Form 144 notice of proposed sale covering 131,370 American Depositary Shares (ADS) with an aggregate market value of approximately $47,064,616.20.

Transaction Details

• Security Class: ADS
• Units to be Sold: 131,370 ADS (~0.23% of the 57,914,782 units outstanding)
• Aggregate Market Value: $47,064,616.20 (implied price of ~$358.26 per ADS)
• Broker: Morgan Stanley Smith Barney LLC
• Approximate Date of Sale: September 8, 2026
• Rule 10b5-1 Plan Adoption Date: June 9, 2026

Origin of Securities

1. Option Exercises: 124,110 ADSs to be acquired upon exercise of stock options over the next three months.
2. RSU Vesting: 7,260 ADSs acquired through restricted stock unit vesting between June 22, 2022, and June 15, 2026.

Trading Significance

Given the large transaction size ($47.1M), this planned disposition represents high trading significance, though it is executed under a pre-established Rule 10b5-1 trading plan adopted on June 9, 2026, and primarily funded by option exercises.